MedTrace Logo

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

NCT06840119 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2026-01-28

No results posted yet for this study

Summary

This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.

Conditions

Interventions

DRUG

IMC-R117C

IV infusion

DRUG

Chemotherapy drug

IV infusion

DRUG

Chemotherapy drug

oral

DRUG

Kinase inhibitor

oral

DRUG

Antiangiogenic Agent

IV infusion

DRUG

Monoclonal antibody

IV infusion

Sponsors & Collaborators

  • Immunocore Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-10
Primary Completion
2026-11-30
Completion
2027-11-30

Countries

  • Australia
  • Belgium
  • Germany
  • Italy
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06840119 on ClinicalTrials.gov